In a disturbing turn of events, the Indian Health Ministry has reported that nine children have died due to alleged consumption of a contaminated cough syrup, Coldrif Cough Syrup, manufactured by Sresan Pharma. All the deceased were under five years old and hailed from the states of Madhya Pradesh and Rajasthan.
Investigation and Findings
Tests conducted by state authorities revealed that samples of the cough syrup contained diethylene glycol (DEG), a toxic substance exceeding permissible limits. The Ministry’s statement highlighted the severity of the findings, stating, “The samples are found to contain DEG beyond the permissible limit,” putting the safety of cough syrups under scrutiny.
State Responses
- Madhya Pradesh has prohibited the sale of Coldrif Cough Syrup and other products manufactured by Sresan Pharma.
- Authorities in Tamil Nadu and Kerala have followed suit, banning the cough syrup as well.
Broader Implications
This incident isn’t isolated; over the years, Indian cough syrups have come under global scrutiny. Notably, in 2022, more than 70 children died in The Gambia following the consumption of contaminated syrups from another manufacturer.
Industry Oversight
In response to the situation, the Indian authorities have launched inspections of 19 pharmaceutical manufacturers across six states to pinpoint lapses in quality control. The focus is to ensure stringent safety protocols are implemented to avoid future tragedies.
The ongoing investigation is critical not just for the families affected, but for restoring public confidence in India’s pharmaceutical industry.